Profile data is unavailable for this security.
About the company
SHANDONG BUCHANG PHARMACEUTICALS CO., LTD. is a China-based company principally engaged in the research, development, manufacture and distribution of Chinese patent medicines. The Company’s main products are compound traditional Chinese medicines, including cerecarton capsules,wenxin granules, as well as danhong injections, among others. Its products are mainly applied to the fields of cardio-cerebrovascular diseases and gynecological diseases. The Company distributes its products within domestic market and to overseas markets, with North China, East China and Central China as its major markets.
- Revenue in CNY (TTM)13.63bn
- Net income in CNY-1.87bn
- Incorporated2001
- Employees8.49k
- LocationShandong Buchang Pharmaceuticals Co LtdNo. 369, Zhonghua West RoadHEZE 274009ChinaCHN
- Phone+86 5 305299167
- Fax+86 5 305299286
- Websitehttp://www.buchang.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
KPC Pharmaceuticals Inc | 7.65bn | 432.35m | 16.66bn | 5.05k | 38.22 | 3.07 | -- | 2.18 | 0.5757 | 0.5757 | 10.20 | 7.15 | 0.8021 | 2.48 | 2.62 | 1,513,702.00 | 4.63 | 5.42 | 7.76 | 9.13 | 43.12 | 43.68 | 5.77 | 5.70 | 1.46 | 53.93 | 0.1688 | 35.75 | -6.99 | 1.64 | 16.05 | 5.79 | -21.33 | 14.87 |
Anhui Huaheng Biotechnology Co Ltd | 2.04bn | 454.44m | 16.86bn | 1.69k | 37.16 | 8.81 | -- | 8.27 | 2.88 | 2.88 | 12.92 | 12.15 | 0.6196 | 5.59 | 8.04 | 1,205,674.00 | 13.71 | 16.74 | 21.59 | 22.41 | 38.49 | 39.21 | 22.13 | 22.34 | 0.4552 | 155.98 | 0.4552 | 25.20 | 36.63 | 35.72 | 40.32 | 42.84 | 82.09 | -- |
Jiang Zhong Pharmaceutical Co Ltd | 4.39bn | 708.29m | 16.90bn | 4.01k | 24.02 | 4.39 | -- | 3.85 | 1.12 | 1.12 | 6.94 | 6.13 | 0.7078 | 4.00 | 15.58 | 1,093,970.00 | 12.36 | 10.82 | 19.43 | 15.08 | 63.88 | 65.02 | 17.46 | 18.17 | 1.26 | -- | 0.021 | 82.88 | 13.00 | 20.12 | 18.40 | 8.54 | 11.47 | 40.99 |
Dizal Jiangsu Pharmaceutical Co Ltd | 40.10m | -1.05bn | 17.87bn | 328.00 | -- | 16.21 | -- | 445.58 | -2.59 | -2.59 | 0.0984 | 2.65 | 0.0204 | -- | 1.52 | 122,263.40 | -53.53 | -- | -66.24 | -- | 93.97 | -- | -2,630.41 | -- | 2.02 | -- | 0.202 | -- | -100.00 | -- | -9.87 | -- | -- | -- |
Chongqing Taiji Industry Group Co Ltd | 15.62bn | 822.12m | 18.78bn | 12.59k | 22.85 | 5.19 | -- | 1.20 | 1.48 | 1.48 | 28.05 | 6.50 | 1.07 | 3.32 | 7.83 | 1,240,976.00 | 5.82 | 0.7814 | 18.62 | 2.35 | 47.39 | 44.03 | 5.46 | 0.8498 | 0.5147 | 6.18 | 0.5658 | 25.76 | 10.58 | 7.88 | 131.99 | 63.55 | 3.86 | 24.57 |
Shandong Buchang Pharmaceuticals Co Ltd | 13.63bn | -1.87bn | 18.90bn | 8.49k | -- | 1.55 | -- | 1.39 | -1.69 | -1.69 | 12.32 | 11.05 | 0.6087 | 1.12 | 9.71 | 1,605,200.00 | -8.86 | 4.93 | -12.07 | 7.05 | 69.25 | 77.42 | -14.56 | 7.18 | 0.5054 | -20.16 | 0.2163 | 109.43 | -5.15 | 1.52 | -218.65 | -- | -17.89 | 0.1039 |
Tonghua Dongbao Pharmaceutical Co Ltd | 3.08bn | 1.17bn | 20.30bn | 3.20k | 17.36 | 2.81 | -- | 6.60 | 0.5863 | 0.5863 | 1.54 | 3.62 | 0.4236 | 0.9223 | 5.06 | 962,270.40 | 16.09 | 18.68 | 16.89 | 19.68 | 79.62 | 78.73 | 37.98 | 39.20 | 4.06 | -- | 0.0204 | 41.73 | 10.69 | 2.69 | -26.17 | 6.85 | -14.75 | 4.56 |
Sinocelltech Group Ltd | 1.89bn | -396.02m | 20.96bn | 2.33k | -- | -- | -- | 11.10 | -0.8893 | -0.8893 | 4.24 | -1.35 | 0.6921 | 0.342 | 5.86 | 808,979.60 | -14.55 | -40.17 | -38.38 | -74.63 | 96.42 | 95.42 | -21.03 | -108.20 | 0.4232 | 1.06 | 1.30 | -- | 84.46 | 264.19 | 23.70 | -- | 37.54 | -- |
Shanghai Allist Pharmaceuticals Co Ltd | 1.62bn | 487.02m | 21.26bn | 870.00 | 43.65 | 5.83 | -- | 13.11 | 1.08 | 1.08 | 3.60 | 8.10 | 0.4513 | 1.96 | 9.77 | 1,863,318.00 | 13.56 | -6.70 | 14.46 | -7.38 | 94.94 | 96.63 | 30.04 | -49.48 | 8.50 | -- | 0.0006 | -- | 49.22 | 152.37 | 614.22 | -- | 152.72 | -- |
Nanjing King-Frind Bchmcl Phrmctcl C Ltd | 4.00bn | 1.02bn | 21.31bn | 1.40k | 20.77 | 3.11 | -- | 5.32 | 0.6346 | 0.6346 | 2.48 | 4.23 | 0.3813 | 0.3692 | 4.83 | 2,867,937.00 | 9.72 | 12.93 | 14.49 | 18.96 | 49.00 | 53.87 | 25.50 | 27.46 | 1.02 | -- | 0.324 | 20.30 | 0.706 | 27.25 | 2.98 | 28.26 | 42.10 | 23.27 |
Data as of Apr 18 2024. Currency figures normalised to Shandong Buchang Pharmaceuticals Co Ltd's reporting currency: Chinese Yuan Renminbi CNY
Holder | Shares | % Held |
---|---|---|
Yinhua Fund Management Co., Ltd.as of 30 Jun 2023 | 4.41m | 0.40% |
China Southern Asset Management Co., Ltd.as of 30 Jun 2023 | 4.09m | 0.37% |
GF Fund Management Co., Ltd.as of 30 Jun 2023 | 3.14m | 0.28% |
China Universal Asset Management Co., Ltd.as of 30 Jun 2023 | 3.12m | 0.28% |
Fullgoal Fund Management Co., Ltd.as of 30 Jun 2023 | 2.39m | 0.22% |
Wanjia Asset Management Co., Ltd.as of 30 Jun 2023 | 2.14m | 0.19% |
Penghua Fund Management Co., Ltd.as of 30 Jun 2023 | 1.22m | 0.11% |
China Asset Management Co., Ltd.as of 30 Jun 2023 | 1.16m | 0.11% |
E Fund Management Co., Ltd.as of 30 Jun 2023 | 1.08m | 0.10% |
Founder Fubon Fund Management Co., Ltd.as of 30 Jun 2023 | 1.06m | 0.10% |
More ▼
Data from 30 Jun 2023 - 29 Feb 2024Source: FactSet Research Systems Inc.